论文信息 - A regulatory perspective on in vitro diagnostics - 字舞流文

A regulatory perspective on in vitro diagnostics

A major outreach effort is under way that recruits scientific and technological expertise in industry and academia to optimize regulatory decision-making for next-generation diagnostic tests.

Scott Gottlieb | Janet Woodcock | J. Woodcock | S. Gottlieb

[1] L. Lesko,et al. Pharmacogenomic data: FDA voluntary and required submission guidance. , 2004, Pharmacogenomics.

[2] L. Lesko,et al. Pharmacogenomics in Drug Development and Regulatory Decision-making: the Genomic Data Submission (GDS) Proposal. , 2004, Pharmacogenomics.

[3] S. Gutman. The role of Food and Drug Administration regulation of in vitro diagnostic devices--applications to genetics testing. , 1999, Clinical chemistry.

[4] J. Woodcock,et al. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective , 2004, Nature Reviews Drug Discovery.

[5] W. McGuire,et al. Current status of estrogen receptors in human breast cancer , 1975, Cancer.

[6] Shiew-Mei Huang,et al. Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Decision Making: Report of the First FDA‐PWG‐PhRMA‐DruSafe Workshop , 2003, Journal of clinical pharmacology.